Natco Pharma gained 2.36% to Rs 71.45 at 11:35 IST on BSE, after the company said on Friday, 19 September 2008, it has launched its nano technology drug Albupax, which is used for the treatment of breast cancer.
The company made this announcement during trading hours today, 19 September 2008.
The stock hit a high of Rs 71.85 and a low of Rs 69.70 so far during the day. The stock has a 52-week high of Rs 179.40 on 1 January 2008 and a 52-week low of Rs 61.05 on 21 July 2008.
The company’s current equity is Rs 28.04 crore. Face value per share is Rs 10.
The current price of Rs 71.45 discounts Q1 June 2008 annualized EPS of Rs 10.96, by a PE multiple of 6.52.
Albupax is the first generic version of the international brand Abraxnae of Abraxis Bio sciences, USA.
Each 100 miligram (mg) vial of Albupax bas been affordably priced at Rs 11,500. The estimated annual Indian market for this product is Rs 150 crore.
In July 2008, Natco Pharma signed a licence and supply agreement with US-based Mylan Inc for the global sale of generic version of Israeli rival Teva's patented drug Copaxone.
Natco Pharma’s net profit 8.6% to Rs 7.68 crore on 5% increase in net sales to Rs 56.51 crore in Q1 June 2008 over Q1 June 2007.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment